LPL Financial LLC Has $4.87 Million Holdings in Organon & Co. $OGN

Key Points

• LPL Financial LLC reduced its stake in Organon & Co. by 28.5%, owning approximately 0.13% of the company, valued at $4.87 million as of its latest SEC filing.
• Organon & Co. reported a net profit margin of 11.15% and an expected EPS of 3.68 for the current fiscal year, despite a 0.8% year-over-year revenue decline.
• The company recently announced a quarterly dividend of $0.02 per share, with an annual yield of 0.9%, to be paid on September 11th.

LPL Financial LLC lessened its position in Organon & Co. (NYSE:OGN - Free Report) by 28.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 327,293 shares of the company's stock after selling 130,394 shares during the period. LPL Financial LLC owned about 0.13% of Organon & Co. worth $4,873,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Treasurer of the State of North Carolina grew its position in Organon & Co. by 0.6% in the 4th quarter. Treasurer of the State of North Carolina now owns 113,120 shares of the company's stock valued at $1,688,000 after buying an additional 710 shares in the last quarter. SBI Securities Co. Ltd. boosted its holdings in shares of Organon & Co. by 17.6% during the first quarter. SBI Securities Co. Ltd. now owns 7,653 shares of the company's stock worth $114,000 after purchasing an additional 1,145 shares during the period. Rafferty Asset Management LLC boosted its holdings in shares of Organon & Co. by 5.6% during the fourth quarter. Rafferty Asset Management LLC now owns 22,627 shares of the company's stock worth $338,000 after purchasing an additional 1,194 shares during the period. Handelsbanken Fonder AB lifted its stake in Organon & Co. by 1.5% in the first quarter. Handelsbanken Fonder AB now owns 81,565 shares of the company's stock valued at $1,215,000 after acquiring an additional 1,200 shares during the last quarter. Finally, Freedom Investment Management Inc. lifted its stake in shares of Organon & Co. by 12.0% in the fourth quarter. Freedom Investment Management Inc. now owns 11,344 shares of the company's stock worth $169,000 after buying an additional 1,218 shares during the last quarter. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

OGN has been the subject of several research analyst reports. Evercore ISI cut shares of Organon & Co. from an "outperform" rating to an "inline" rating in a research note on Friday, May 2nd. BNP Paribas upgraded shares of Organon & Co. to a "strong-buy" rating in a research note on Thursday, May 22nd. Morgan Stanley dropped their price objective on shares of Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Finally, Piper Sandler dropped their price objective on shares of Organon & Co. from $24.00 to $18.00 and set an "overweight" rating for the company in a research note on Thursday, May 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $18.00.

Organon & Co. Price Performance

NYSE:OGN traded down $0.08 during mid-day trading on Monday, reaching $9.37. 1,381,539 shares of the company were exchanged, compared to its average volume of 4,485,420. Organon & Co. has a 12 month low of $8.01 and a 12 month high of $23.10. The company has a fifty day moving average of $9.75 and a 200 day moving average of $11.60. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 11.98. The stock has a market cap of $2.43 billion, a PE ratio of 3.48, a PEG ratio of 0.98 and a beta of 0.60.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, topping the consensus estimate of $0.94 by $0.06. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. The company had revenue of $1.59 billion during the quarter, compared to analysts' expectations of $1.55 billion. During the same quarter in the previous year, the company earned $1.12 EPS. Organon & Co.'s revenue was down .8% on a year-over-year basis. On average, research analysts anticipate that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 11th. Shareholders of record on Friday, August 15th will be issued a $0.02 dividend. This represents a $0.08 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, August 15th. Organon & Co.'s payout ratio is currently 2.97%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.